世界の心血管疾患治療薬市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV03769)
◆英語タイトル:Global Cardiovascular Disease Drugs Market Insights and Forecast to 2026
◆商品コード:QYR20NV03769
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:111
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは心血管疾患治療薬の世界市場について調査・分析した資料です。種類別(ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロトレル、その他)の市場規模、用途別(虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別心血管疾患治療薬の競争状況、市場シェア
・世界の心血管疾患治療薬市場:種類別市場規模 2015年-2020年(ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロトレル、その他)
・世界の心血管疾患治療薬市場:種類別市場規模予測 2021年-2026年(ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロトレル、その他)
・世界の心血管疾患治療薬市場:用途別市場規模 2015年-2020年(虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他)
・世界の心血管疾患治療薬市場:用途別市場規模予測 2021年-2026年(虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他)
・北米の心血管疾患治療薬市場分析:米国、カナダ
・ヨーロッパの心血管疾患治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの心血管疾患治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の心血管疾患治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの心血管疾患治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):AstraZeneca、Johnson&Johnson、Pfizer、Sanofi、Merck、Daiichi Sankyo Company Limited、Novartis、Bayer、Takeda Pharmaceutical、Hoffmann-La Roche、United Therapeutics Corporation、Actelion Pharmaceuticals、Boehringer Ingelheim、Astellas Pharma
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Market Analysis and Insights: Global Cardiovascular Disease Drugs Market
The global Cardiovascular Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Cardiovascular Disease Drugs Scope and Market Size
Cardiovascular Disease Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cardiovascular Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Cardiovascular Disease Drugs market is segmented into
Heparin
Coumadin
Sectral
Zebeta
Lopressor
Toprol XL
Norvasc
Lotrel
Others

Segment by Application, the Cardiovascular Disease Drugs market is segmented into
Asischemic Heart Disease
Dyslipidemia
Stroke
Thrombosis
Atherosclerosis
Coronary Artery Diseases
Peripheral Artery Disease
Others

Regional and Country-level Analysis
The Cardiovascular Disease Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cardiovascular Disease Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cardiovascular Disease Drugs Market Share Analysis
Cardiovascular Disease Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cardiovascular Disease Drugs business, the date to enter into the Cardiovascular Disease Drugs market, Cardiovascular Disease Drugs product introduction, recent developments, etc.

The major vendors covered:
AstraZeneca
Johnson&Johnson
Pfizer
Sanofi
Merck
Daiichi Sankyo Company Limited
Novartis
Bayer
Takeda Pharmaceutical
Hoffmann-La Roche
United Therapeutics Corporation
Actelion Pharmaceuticals
Boehringer Ingelheim
Astellas Pharma

【レポートの目次】

1 Study Coverage
1.1 Cardiovascular Disease Drugs Product Introduction
1.2 Market Segments
1.3 Key Cardiovascular Disease Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cardiovascular Disease Drugs Market Size Growth Rate by Type
1.4.2 Heparin
1.4.3 Coumadin
1.4.4 Sectral
1.4.5 Zebeta
1.4.6 Lopressor
1.4.7 Toprol XL
1.4.8 Norvasc
1.4.9 Lotrel
1.4.10 Others
1.5 Market by Application
1.5.1 Global Cardiovascular Disease Drugs Market Size Growth Rate by Application
1.5.2 Asischemic Heart Disease
1.5.3 Dyslipidemia
1.5.4 Stroke
1.5.5 Thrombosis
1.5.6 Atherosclerosis
1.5.7 Coronary Artery Diseases
1.5.8 Peripheral Artery Disease
1.5.9 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Cardiovascular Disease Drugs Market Size, Estimates and Forecasts
2.1.1 Global Cardiovascular Disease Drugs Revenue 2015-2026
2.1.2 Global Cardiovascular Disease Drugs Sales 2015-2026
2.2 Global Cardiovascular Disease Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Cardiovascular Disease Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cardiovascular Disease Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Cardiovascular Disease Drugs Competitor Landscape by Players
3.1 Cardiovascular Disease Drugs Sales by Manufacturers
3.1.1 Cardiovascular Disease Drugs Sales by Manufacturers (2015-2020)
3.1.2 Cardiovascular Disease Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Cardiovascular Disease Drugs Revenue by Manufacturers
3.2.1 Cardiovascular Disease Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Cardiovascular Disease Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cardiovascular Disease Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cardiovascular Disease Drugs Revenue in 2019
3.2.5 Global Cardiovascular Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cardiovascular Disease Drugs Price by Manufacturers
3.4 Cardiovascular Disease Drugs Manufacturing Base Distribution, Product Types
3.4.1 Cardiovascular Disease Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cardiovascular Disease Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Cardiovascular Disease Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Cardiovascular Disease Drugs Market Size by Type (2015-2020)
4.1.1 Global Cardiovascular Disease Drugs Sales by Type (2015-2020)
4.1.2 Global Cardiovascular Disease Drugs Revenue by Type (2015-2020)
4.1.3 Cardiovascular Disease Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cardiovascular Disease Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Cardiovascular Disease Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Cardiovascular Disease Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Cardiovascular Disease Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cardiovascular Disease Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Cardiovascular Disease Drugs Market Size by Application (2015-2020)
5.1.1 Global Cardiovascular Disease Drugs Sales by Application (2015-2020)
5.1.2 Global Cardiovascular Disease Drugs Revenue by Application (2015-2020)
5.1.3 Cardiovascular Disease Drugs Price by Application (2015-2020)
5.2 Cardiovascular Disease Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Cardiovascular Disease Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Cardiovascular Disease Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Cardiovascular Disease Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Cardiovascular Disease Drugs by Country
6.1.1 North America Cardiovascular Disease Drugs Sales by Country
6.1.2 North America Cardiovascular Disease Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cardiovascular Disease Drugs Market Facts & Figures by Type
6.3 North America Cardiovascular Disease Drugs Market Facts & Figures by Application

7 Europe
7.1 Europe Cardiovascular Disease Drugs by Country
7.1.1 Europe Cardiovascular Disease Drugs Sales by Country
7.1.2 Europe Cardiovascular Disease Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cardiovascular Disease Drugs Market Facts & Figures by Type
7.3 Europe Cardiovascular Disease Drugs Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Cardiovascular Disease Drugs by Region
8.1.1 Asia Pacific Cardiovascular Disease Drugs Sales by Region
8.1.2 Asia Pacific Cardiovascular Disease Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cardiovascular Disease Drugs Market Facts & Figures by Type
8.3 Asia Pacific Cardiovascular Disease Drugs Market Facts & Figures by Application

9 Latin America
9.1 Latin America Cardiovascular Disease Drugs by Country
9.1.1 Latin America Cardiovascular Disease Drugs Sales by Country
9.1.2 Latin America Cardiovascular Disease Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cardiovascular Disease Drugs Market Facts & Figures by Type
9.3 Central & South America Cardiovascular Disease Drugs Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Cardiovascular Disease Drugs by Country
10.1.1 Middle East and Africa Cardiovascular Disease Drugs Sales by Country
10.1.2 Middle East and Africa Cardiovascular Disease Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cardiovascular Disease Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Cardiovascular Disease Drugs Market Facts & Figures by Application

11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Cardiovascular Disease Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.2 Johnson&Johnson
11.2.1 Johnson&Johnson Corporation Information
11.2.2 Johnson&Johnson Description and Business Overview
11.2.3 Johnson&Johnson Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Johnson&Johnson Cardiovascular Disease Drugs Products Offered
11.2.5 Johnson&Johnson Related Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description and Business Overview
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Cardiovascular Disease Drugs Products Offered
11.3.5 Pfizer Related Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Description and Business Overview
11.4.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Sanofi Cardiovascular Disease Drugs Products Offered
11.4.5 Sanofi Related Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Description and Business Overview
11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merck Cardiovascular Disease Drugs Products Offered
11.5.5 Merck Related Developments
11.6 Daiichi Sankyo Company Limited
11.6.1 Daiichi Sankyo Company Limited Corporation Information
11.6.2 Daiichi Sankyo Company Limited Description and Business Overview
11.6.3 Daiichi Sankyo Company Limited Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Products Offered
11.6.5 Daiichi Sankyo Company Limited Related Developments
11.7 Novartis
11.7.1 Novartis Corporation Information
11.7.2 Novartis Description and Business Overview
11.7.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Novartis Cardiovascular Disease Drugs Products Offered
11.7.5 Novartis Related Developments
11.8 Bayer
11.8.1 Bayer Corporation Information
11.8.2 Bayer Description and Business Overview
11.8.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Bayer Cardiovascular Disease Drugs Products Offered
11.8.5 Bayer Related Developments
11.9 Takeda Pharmaceutical
11.9.1 Takeda Pharmaceutical Corporation Information
11.9.2 Takeda Pharmaceutical Description and Business Overview
11.9.3 Takeda Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Takeda Pharmaceutical Cardiovascular Disease Drugs Products Offered
11.9.5 Takeda Pharmaceutical Related Developments
11.10 Hoffmann-La Roche
11.10.1 Hoffmann-La Roche Corporation Information
11.10.2 Hoffmann-La Roche Description and Business Overview
11.10.3 Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Hoffmann-La Roche Cardiovascular Disease Drugs Products Offered
11.10.5 Hoffmann-La Roche Related Developments
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Cardiovascular Disease Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.12 Actelion Pharmaceuticals
11.12.1 Actelion Pharmaceuticals Corporation Information
11.12.2 Actelion Pharmaceuticals Description and Business Overview
11.12.3 Actelion Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Actelion Pharmaceuticals Products Offered
11.12.5 Actelion Pharmaceuticals Related Developments
11.13 Boehringer Ingelheim
11.13.1 Boehringer Ingelheim Corporation Information
11.13.2 Boehringer Ingelheim Description and Business Overview
11.13.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Boehringer Ingelheim Products Offered
11.13.5 Boehringer Ingelheim Related Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Corporation Information
11.14.2 Astellas Pharma Description and Business Overview
11.14.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Astellas Pharma Products Offered
11.14.5 Astellas Pharma Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Cardiovascular Disease Drugs Market Estimates and Projections by Region
12.1.1 Global Cardiovascular Disease Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Cardiovascular Disease Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.2.2 North America: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cardiovascular Disease Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cardiovascular Disease Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cardiovascular Disease Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

...

【掲載企業】

AstraZeneca、Johnson&Johnson、Pfizer、Sanofi、Merck、Daiichi Sankyo Company Limited、Novartis、Bayer、Takeda Pharmaceutical、Hoffmann-La Roche、United Therapeutics Corporation、Actelion Pharmaceuticals、Boehringer Ingelheim、Astellas Pharma

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の心血管疾患治療薬市場2026:インサイト・予測(Global Cardiovascular Disease Drugs Market Insights and Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。